Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2026 03:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment optionsDAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as...
May 21, 2026 17:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...